VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

A clinical trial led by an Indiana University School of Medicine researcher found that weekly doses of semaglutide - a ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

A new study reports that measurements that detect body fat are a more accurate predictor of mortality risk than body mass ...

A clinical trial for semaglutide, the active ingredient in Ozempic, found that it improved blood sugar control in people with ...

Individuals with MASLD with a lean vs nonlean body type have increased mortality and cardiovascular disease, among other outcomes.

Danish drugmaker Novo Nordisk is working to bring its blockbuster drug Ozempic to India “as soon as possible", Dr Yan Cai, ...

A new algorithm enables smartwatch fitness trackers to more accurately monitor energy expenditure of people with obesity ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

First p articipants with obesity or o verweight w ith at least one w eight- r elated c omorbidity have been d osed in a U.

China NMPA approves Innovent’s mazdutide, first dual GCG/GLP-1 receptor agonist for chronic weight management: San Francisco, US Monday, June 30, 2025, 12:00 Hrs [IST] Innovent ...

Innovation in obesity treatments, Alzheimer's detection and medical-device applications is setting the stage for a number of ...